This article is more than 5 years old. Information may no longer be current.
Mount Sinai Health System to use artificial intelligence to track patients at risk for chronic kidney disease
Click Here to Manage Email Alerts
Mount Sinai Health System and RenalytixAI Plc have entered into a multiyear license and collaboration agreement to use artificial intelligence to improve chronic kidney disease detection, management and treatment for patients with diabetes and for other at-risk, large-scale patient populations.
Starting next year, a team will apply artificial intelligence (AI) to Mount Sinai Health System’s patient data warehouse biorepository, which contains more than 3,000,000 patient health records and 43,000 patient records, to help more accurately detect and manage kidney disease.
“What AI will allow us to do is identify those at risk of CKD early and allow us to stratify patients with regard to risk for progression of CKD,” Barbara Murphy, MD, MB, BAO, BCh, FRCPI, chair of the department of medicine, the Murray M. Rosenberg professor of medicine, and dean for clinical integration and population health at the Icahn School of Medicine at Mount Sinai, told Healio Nephrology. “It will guide early identification, management and monitoring of patients.”
RenalytixAI will use de-identified clinical data to create an advanced learning system to monitor and flag patients at risk for kidney disease and costly unplanned “crashes” into dialysis, according to a press release from Mount Sinai Health System. The first product launch is anticipated in 2019 and will target preventable dialysis and chronic kidney disease costs. Additional major U.S.-based health care systems are expected to participate in clinical utility data development and product launch, according to the release.
“Our ability to apply the power of artificial intelligence against such a deep repository of clinical data in combination with prognostic biomarkers has the potential to change the game for all of our patients with diabetes and other populations at risk for kidney disease,” Murphy said in the release.
Approximately 1 million patients cared for in the Mount Sinai Health System are either diagnosed with type 2 diabetes or are of African ancestry, two of the major at-risk population segments for kidney disease, according to the release.
Reference:
www.mountsinai.org/about/newsroom/2018/mount-sinai-and-renalytixai-launch-groundbreaking-artificial-intelligence-solution-for-improved-kidney-disease-management-and-patient-care
Disclosure: Murphy is chair of the scientific advisory board of RenalytixAI.